Drug Type Small molecule drug |
Synonyms GS-5245 |
Mechanism COVID19 non structural protein 8 modulators, COVID19 replicase polyprotein 1ab inhibitors, RNA polymerase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H19N5O5 |
InChIKeyYIHPGVCWGSURHO-VSBTWAGUSA-N |
CAS Registry2647441-36-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | JP | 05 Nov 2022 | |
COVID-19 | Phase 3 | BR | 05 Nov 2022 | |
COVID-19 | Phase 3 | BG | 05 Nov 2022 | |
COVID-19 | Phase 3 | CA | 05 Nov 2022 | |
COVID-19 | Phase 3 | CZ | 05 Nov 2022 | |
COVID-19 | Phase 3 | FR | 05 Nov 2022 | |
COVID-19 | Phase 3 | HU | 05 Nov 2022 | |
COVID-19 | Phase 3 | IT | 05 Nov 2022 | |
COVID-19 | Phase 3 | MX | 05 Nov 2022 | |
COVID-19 | Phase 3 | PL | 05 Nov 2022 |
Phase 3 | - | dwoaxxzlgd(sftmknrkaj) = obeldesivir in non-hospitalized participants without risk factors for developing severe COVID-19 did not meet its primary endpoint of improvement in time to symptom alleviation. ooolsxrhwa (dmwcxrxxst ) Not Met View more | Negative | 06 Feb 2024 |